Drug intelligence / Profile preview

SYNT002

Development stage: Preclinical
Lead developer: Alexion Pharmaceuticals

Overview

SYNT002 is a drug candidate developed by Syntimmune, a clinical-stage biotechnology company focused on FcRn biology. It is part of their FcRn-targeted programs and is currently in preclinical development. The drug is intended for the treatment of IgG-mediated autoimmune diseases, aiming to achieve FcRn-IgG blockade.

Targets

FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on SYNT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYNT002.

Explore the full profile